Principal Investigator
Dionysios Watson
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20240640
Clinical Trial Summary
A randomized phase II study of sotorasib versus continued consolidation durvalumab in patients with KRAS G12C mutant locally advanced non-small cell lung cancer (LA-NSCLC) with persistent ctDNA defined minimal residual disease
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Thoracic Oncology
Contact Information
Phone Number
+1 (305) 2434624